Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 18,800 full-time employees in 69 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
For further information please contact:
|
Media: |
Investors: |
|
Mike Rulis |
Outside North America: |
|
Tel (direct):
(+45) 4442 3573 |
Peter Haahr |
|
|
Tel (direct):
(+45) 4442 1207 |
|
|
|
|
|
Palle Holm Olesen |
|
|
Tel (direct):
(+45) 4442 6175 |
|
|
|
|
|
In North America: |
|
|
Christian Kanstrup |
|
|
Tel (direct):
(+1) 609 919 7937
|
Stock Exchange Announcement No 54 / 2004
